TG Therapeutics Raises 2026 Revenue Guidance to About $1 Billion
TG Therapeutics reported Q3 2026 revenue of $259.9M and net income of $55.5M. The company raised its 2026 revenue guidance to $1B and BRIUMVI U.S. net product revenue to $915M-$920M. Cash and investments totaled $556.7M. BRIUMVI showed strong performance, with increased targets supported by IV business momentum. Clinical trials for BRIUMVI and Azer-cel are ongoing.
How this was made
The 30-second read
Why it matters
The guidance raise and trial outcomes provide fresh, material information that can move the stock, making the article highly actionable for traders.
Market read
The news directly impacts TG Therapeutics' valuation and may influence peer biotech stocks.
What to watch
Potential regulatory hurdles for the subcutaneous formulation and competition from other MS drugs could temper upside.
Background
TG Therapeutics reported Q3 2026 results and announced a significant increase in its full‑year revenue target, alongside positive Phase 3 trial data for BRIUMVI.
Ticker impact
TG Therapeutics raised its 2026 total revenue guidance to about $1 billion, up from prior expectations.
upward pressure as investors price in higher revenue outlook
The company disclosed fresh revenue guidance and trial data that were not previously public, providing a clear catalyst for buying.
Market effects
Biotech sector may see modest uplift as a small-cap guidance raise highlights potential in MS therapies.
U.S. biotech investors likely to react positively; limited broader market effect.
Limited to investors tracking niche multiple sclerosis treatments.
Counterpoint
If the guidance assumes optimistic market uptake, any delay in subcutaneous launch could disappoint, prompting a sell-off.
Key entities
- companyTG Therapeutics
Biopharmaceutical company developing BRIUMVI for multiple sclerosis.
